Department of Clinical Bacteriology, Parasitology, Zoonoses and Geographical Medicine, University Hospital of Heraklion, 711, 10 Heraklion, Crete, Greece.
Future Microbiol. 2011 Sep;6(9):1099-109. doi: 10.2217/fmb.11.91.
To describe the clinical significance and antibiotic susceptibilities of nontuberculous mycobacteria (NTM) isolated from patients in Crete, Greece between January 2000 and December 2009.
PATIENTS & METHODS: NTM identification was performed using conventional bacteriological methods and confirmed by molecular characterization with commercially available assays. Rare and novel species were identified by sequencing of the 16SrRNA and of the hsp65 genes. Antibiotic susceptibility testing was performed by E-test. Rapidly growing (RGM) and slowly growing (SGM) NTM were tested against 14 antimicrobials, including nine common ones, except for Mycobacterium avium and Mycobacterium intracellulare (MAC) complex isolates that were tested only against azithromycin, clarithromycin, linezolid and moxifloxacin.
During the study period, 290 positive samples for NTM were recovered from 207 patients. Among the positive samples, 150 were identified as SGM and 57 as RGM. Overall, 50 patients met American Thoracic Society criteria for disease due to NTM, 42 by SGM and eight by RGM. Risk factors in patients with NTM disease were underlying lung diseases, mainly chronic obstructive pulmonary disease and asthma, smoking, rheumatoid arthritis, AIDS, alcohol or drug abuse, malignancies and bronchiectasis. The most common disease-causing species were the MAC complex (n = 25) followed by Mycobacterium kansasii (n = 10). Amikacin was the most active drug for RGM with 100% susceptibility. Macrolides were very active against isolates of the MAC complex, while tigecycline had excellent activity in vitro against RGM. M. kansasii was the most susceptible NTM species in vitro.
Our study is the first to describe the clinical significance, risk factors and susceptibility patterns of NTM isolates in a Greek population.
描述 2000 年 1 月至 2009 年 12 月间希腊克里特岛患者分离的非结核分枝杆菌(NTM)的临床意义和抗生素敏感性。
使用常规细菌学方法进行 NTM 鉴定,并通过商业上可用的检测方法进行分子特征鉴定来确认。通过 16SrRNA 和 hsp65 基因测序来鉴定稀有和新型物种。通过 E-试验进行抗生素敏感性测试。对快速生长(RGM)和缓慢生长(SGM)NTM 进行了 14 种抗生素的测试,包括 9 种常用抗生素,除了分枝杆菌属和细胞内分枝杆菌(MAC)复合体分离株仅对阿奇霉素、克拉霉素、利奈唑胺和莫西沙星进行测试。
在研究期间,从 207 名患者中回收了 290 份 NTM 阳性样本。在阳性样本中,有 150 份被鉴定为 SGM,57 份为 RGM。总体而言,有 50 名患者符合美国胸科学会(ATS)的 NTM 疾病标准,其中 42 名是由 SGM 引起的,8 名是由 RGM 引起的。NTM 疾病患者的危险因素是基础肺部疾病,主要是慢性阻塞性肺疾病和哮喘、吸烟、类风湿关节炎、艾滋病、酒精或药物滥用、恶性肿瘤和支气管扩张症。最常见的致病物种是 MAC 复合体(n = 25),其次是堪萨斯分枝杆菌(n = 10)。阿米卡星是 RGM 最有效的药物,敏感性为 100%。大环内酯类药物对 MAC 复合体的分离株非常有效,而替加环素对 RGM 具有出色的体外活性。堪萨斯分枝杆菌是最敏感的 NTM 物种。
我们的研究首次描述了希腊人群中 NTM 分离株的临床意义、危险因素和药敏模式。